Full name

A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus (SLE) (BE-EARLY)

NCT Number
NCT06411249
Geography
US
Non-US
Locations

Argentina, Brazil, France, Germany, Italy, Japan, Mexico, Spain, United States

Primary Endpoints

Part A: Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 52

Order
1
Disease
SLE
Menu title
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) (BE-EARLY)
Version
NMA 2025
Phase
4
Status
Recruiting